| April 7, 2003 | ||||||||||
In Print![]() Photo by Graham Ramsay
Focus: Last March, a journal reported the apparently miraculous recovery of four patients with a rare blood cancer, hypereosinophilic syndrome (HES). The patients were brought back from the brink of death by taking the much-touted drug, Gleevec (imatinib). Now, Gary Gilliland, Elizabeth Stover, Jan Cools (l to r), and colleagues have confirmed these results and have found out how the drug works against the disease. Their research could provide a new model for the origin of HES and similar cancers.
|
|
HeadlinesStroke Risk Increases with Every Cigarette Smoked, Study Finds Antibody Therapy Can Increase the Effectiveness of Cancer Vaccine, Preliminary Study Suggests Unique Experimental Drug Shows Antidepressant Effects
UpcomingRobert H. Ebert LectureLatina Health: Beyond Competency
Jane Delgado, National Alliance for Hispanic Health
|
Spotlight
Student Scene
Lab WorksA multimedia site featuring Harvard Medical research
The 60-second SurveyTake a survey to tell us how you use WebWeekly. |
|||||||
Calendar | Jobs | Harvard Medical School Home | Hospitals | Back Issues | Feedback | Home |